Comparison · Source check: September 27, 2026
Testosterone cypionate provider documents compared: identity, evidence and price units
An alphabetical review of CoreAge Rx, Hone Health, and TRT Nation public descriptions, compounded-product statements, exact-label limits, and price units.
Editorial research from public documents. No patient testing or clinician review is claimed.
A comparison becomes misleading when three offers share the words testosterone cypionate and the missing details are treated as identical. One may publish a concentration, another describe a treatment package, and another quote a vial price alongside a membership. This comparison asks what each public record actually identifies before interpreting its price or medical claims.
Cypionate Facts was prepared for the CoreAge Rx publishing network, an affiliation readers should consider when evaluating this coverage. Providers appear alphabetically, without ratings, preferred placement, or clinical endorsement. This comparison examines official descriptions and primary medical sources checked on September 27, 2026. It includes no patient testing, pharmacy audits, or invented outcome scores.
CoreAge Rx: the concentration is explicit, the full formula is not
CoreAge’s public description identifies injectable testosterone cypionate at 200 mg/mL and a starting $129 monthly amount. It expressly describes compounding in the United States. The full ingredient list, container details, and individual dispensing pharmacy are not established by the page. The concentration must not be interpreted as a personal dose or the length of a supply.
Our CoreAge cypionate review separates these verified and unresolved facts. A company’s bottle photograph, another provider’s label, or a stated supply period cannot complete the missing record. The actual prescribed formulation and cost record would be needed to resolve those omissions. Public descriptions alone do not establish access to treatment, the medicine ultimately supplied, or its suitability for an individual.
Hone Health: the public pages use different price units
Hone’s cypionate product page explicitly offers the injections and calls the product compounded. The headline starts at $28 per month plus membership. However, its Plus membership record describes cypionate starting at $28 per vial, with a $135 monthly membership and separate initial or confirmatory testing expenses. A vial is not automatically a month of treatment.
The membership overview describes Basic, Plus, and Premium, whereas the product-page FAQ describes only Basic and Premium. This review preserves those differences rather than selecting a cheaper interpretation. Our Hone review explains the offer without inferring the concentration, full inactive ingredients, exact manufacturer, or individual total from those public pages.
TRT Nation: a named ingredient within a broader package
TRT Nation’s separate 2026 FAQ names testosterone cypionate in a described 2.5-month package and shows $99.99 per month. Its cost article instead uses $99 per month. Laboratory work is separate, with $129 shown for the service’s TRT testing. These amounts do not establish the exact charge, quantity, or clinical plan for a particular patient.
The main FAQ says its medications come from US compounding pharmacies. That is a source-category claim, not identification of the exact compounder and formula that would be supplied. Its listed additional prescription item should not be assumed necessary for everyone. Read the TRT Nation cypionate review for why these details cannot be compressed into a simple same-medicine price comparison.
Identify the regulatory category before comparing labels
An active ingredient can appear in an approved brand product, an approved generic, and a compounded preparation. These categories do not carry the same regulatory evidence. The FDA generic-drug resource describes the requirements for approved generics, while its compounding explanation states that compounded medicines lack FDA premarket review and approval.
A pharmacy-registration statement, prescription requirement, or claim that an ingredient is FDA-approved does not establish approval of an entire compounded formula. Ask for the medicine actually proposed, not simply an assurance that it contains cypionate. The excipients guide explains why inactive ingredients remain part of that identity, particularly when a reader has a known ingredient concern.
Keep route and concentration out of self-directed comparisons
The exact Depo-Testosterone label concerns an intramuscular preparation. It does not show that every online cypionate offer has the same formula or approved route. A provider’s discussion of another route needs to be understood in relation to the actual prescription and relevant evidence. Our route guide keeps that question with the prescriber and pharmacist.
Likewise, a larger concentration number does not identify a better treatment or a longer supply. The concentration, dose, and volume guide explains the different concepts without calculations. This comparison contains no syringe instructions, injection technique, conversion, or suggested administration schedule. Price arithmetic cannot replace a professional explanation of a prescription.
Clinical assessment and monitoring are separate evidence questions
The Endocrine Society’s July 2026 statement emphasizes reliable diagnostic confirmation and assessment of contributors to low testosterone. It also retains continuing risk and benefit review. A service’s ability to advertise or ship medication is not evidence that a reader meets the clinical requirements for it. Discuss future fertility and other relevant medical history before a treatment decision.
Ask who monitors symptom response, adverse effects, blood pressure, blood counts, and appropriate prostate concerns. FDA’s current information reports June 2026 requested labeling revisions, while the inspected Depo document has an older internal revision. The evolving record does not justify bypassing assessment or calling every injection risk-free. No personal laboratory targets or timetable are supplied here. The FDA page describes TRAVERSE evidence from a particular testosterone gel study. That is useful regulatory context, but it is not a trial comparing these three providers or their compounded cypionate preparations. Keeping the studied formulation visible prevents a class-level discussion from becoming an unsupported finished-product endorsement.
Unanswered fields limit what a comparison can conclude
A meaningful cost record would identify the actual product, concentration, container quantity, price period, membership obligations, and separate assessment costs. An unknown field should remain unknown; it cannot be copied from a competitor or reconstructed from a sales-page number. A written medicine record and a written cost explanation answer different questions, and neither substitutes for the clinical assessment of treatment.
An alphabetical document comparison can expose ambiguity without recommending a provider or medicine. A low starting figure and a recognizable ingredient cannot establish equivalent products or better patient outcomes. The findings here concern the scope and limits of public statements. They do not supply an enrollment recommendation, a treatment ranking, or evidence that any listed service is appropriate for a particular reader.
Source notes
These links identify the records used in this article. A claim about one named medicine does not describe every product with the same ingredient.
- CoreAge Rx: Injectable Testosterone CypionateProvider product page · Checked 2026-09-27
- TRT Nation: Separate 2026 Frequently Asked QuestionsProvider product and price description · Checked 2026-09-27
- TRT Nation: Cost and Process, updated April 2026Provider cost information · Checked 2026-09-27
- TRT Nation: Main Frequently Asked QuestionsProvider pharmacy and service information · Checked 2026-09-27
- Hone Health: Testosterone Cypionate InjectionsProvider product page · Checked 2026-09-27
- Hone Health: Plus Membership for MenProvider medication and membership pricing · Checked 2026-09-27
- Hone Health: Basic, Plus and Premium Membership OverviewProvider membership terms · Checked 2026-09-27
- FDA: Generic Drugs Questions and AnswersRegulatory explanation · Checked 2026-09-27
- FDA: Understanding the Risks of Compounded DrugsRegulatory explanation · Checked 2026-09-27
- Pfizer: Depo-Testosterone prescribing information, revised September 2025Exact product labeling · Checked 2026-09-27
- Endocrine Society: Statement on Testosterone Replacement Therapy, July 16, 2026Current professional society statement · Checked 2026-09-27
- FDA: Testosterone Information and June 2026 labeling requestsCurrent regulatory information · Checked 2026-09-27